Agustín Conde-Agudelo1, Roberto Romero, Juan Pedro Kusanovic. 1. Perinatology Research Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
Abstract
OBJECTIVE: To determine the efficacy and safety of nifedipine as a tocolytic agent in women with preterm labor. STUDY DESIGN: A systematic review and metaanalysis of randomized controlled trials. RESULTS: Twenty-six trials (2179 women) were included. Nifedipine was associated with a significant reduction in the risk of delivery within 7 days of initiation of treatment and before 34 weeks' gestation, respiratory distress syndrome, necrotizing enterocolitis, intraventricular hemorrhage, neonatal jaundice, and admission to the neonatal intensive care unit when compared with β₂-adrenergic-receptor agonists. There was no difference between nifedipine and magnesium sulfate in tocolytic efficacy. Nifedipine was associated with significantly fewer maternal adverse events than β₂-adrenergic-receptor agonists and magnesium sulfate. Maintenance nifedipine tocolysis was ineffective in prolonging gestation or improving neonatal outcomes when compared with placebo or no treatment. CONCLUSION: Nifedipine is superior to β₂-adrenergic-receptor agonists and magnesium sulfate for tocolysis in women with preterm labor.
OBJECTIVE: To determine the efficacy and safety of nifedipine as a tocolytic agent in women with preterm labor. STUDY DESIGN: A systematic review and metaanalysis of randomized controlled trials. RESULTS: Twenty-six trials (2179 women) were included. Nifedipine was associated with a significant reduction in the risk of delivery within 7 days of initiation of treatment and before 34 weeks' gestation, respiratory distress syndrome, necrotizing enterocolitis, intraventricular hemorrhage, neonatal jaundice, and admission to the neonatal intensive care unit when compared with β₂-adrenergic-receptor agonists. There was no difference between nifedipine and magnesium sulfate in tocolytic efficacy. Nifedipine was associated with significantly fewer maternal adverse events than β₂-adrenergic-receptor agonists and magnesium sulfate. Maintenance nifedipine tocolysis was ineffective in prolonging gestation or improving neonatal outcomes when compared with placebo or no treatment. CONCLUSION:Nifedipine is superior to β₂-adrenergic-receptor agonists and magnesium sulfate for tocolysis in women with preterm labor.
Authors: James F King; Vicki Flenady; Dimitri Papatsonis; Gustaaf Dekker; Bruno Carbonne Journal: Aust N Z J Obstet Gynaecol Date: 2003-06 Impact factor: 2.100
Authors: G J Valenzuela; L Sanchez-Ramos; R Romero; H M Silver; W D Koltun; L Millar; J Hobbins; W Rayburn; G Shangold; J Wang; J Smith; G W Creasy Journal: Am J Obstet Gynecol Date: 2000-05 Impact factor: 8.661
Authors: R Romero; B M Sibai; L Sanchez-Ramos; G J Valenzuela; J C Veille; B Tabor; K G Perry; M Varner; T M Goodwin; R Lane; J Smith; G Shangold; G W Creasy Journal: Am J Obstet Gynecol Date: 2000-05 Impact factor: 8.661
Authors: Brahm Seymour Coler; Oksana Shynlova; Adam Boros-Rausch; Stephen Lye; Stephen McCartney; Kelycia B Leimert; Wendy Xu; Sylvain Chemtob; David Olson; Miranda Li; Emily Huebner; Anna Curtin; Alisa Kachikis; Leah Savitsky; Jonathan W Paul; Roger Smith; Kristina M Adams Waldorf Journal: J Clin Med Date: 2021-06-29 Impact factor: 4.241